LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer
July 18th 2017A study presented by researchers from Massachusetts General Hospital (MGH), which queried the effect of thoracic radiotherapy and immune checkpoint inhibition on the risk of pneumonitis or immune-related adverse events (irAEs), found that radiotherapy did not increase patient risk for pneumonitis and that elevated expression of lactate dehydrogenase (LDH) could be a predictor of grade 2 or higher irAEs.
Read More
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
July 17th 2017In a discussion on state-of-the-art uses for immunotherapy in the management of non—small cell lung cancer (NSCLC) at the American Society of Clinical Oncology Annual Meeting, oncologists shared their experiences with managing toxicities from immunotherapy and discussed the role of immunotherapy in specific patient populations.
Read More
An Early Stage Safety, Efficacy Study for Atezolizumab Plus Daratumumab in Advanced NSCLC
July 17th 2017An early stage international clinical trial is actively enrolling patients with relapsed, advanced or metastatic non—small cell lung cancer (NSCLC) to evaluate response to a combination of atezolizumab and daratumumab, according to a study at the 2017 Annual Meeting of the American Society of Clinical Oncology that detailed the trial design.
Read More
Managing heavily pretreated, often less fit, patients with relapsed/refractory multiple myeloma is a challenge in routine practice, as illustrated by the fact progression-free survival remains short, although daratumumab-based combination therapies are proven effective, according to results presented during a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.
Read More
Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma
July 17th 2017A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.
Read More
Updated trial results at the 2017 Annual Meeting of the American Society of Clinical Oncology showed the combinations of daratumumab with either lenalidomide and dexamethasone or bortezomib and dexamethasone prolonged progression-free survival for patients with relapsed refractory multiple myeloma.
Read More
New Science Paper Questions Sequential Role of Lymph Nodes in CRC Metastases
July 10th 2017A new study, published by researchers at Massachusetts General Hospital, has questioned the traditional model of cancer metastases that implicates lymph nodes in helping seed cancer cells at distant sites.
Read More
New Flow Cytometry-Based Test Approved for Certain Leukemias and Lymphomas
July 3rd 2017A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.
Read More
Nivolumab Improved Patient-Reported QOL Compared With Investigator's Choice: CheckMate 141
June 28th 2017The study, published in Lancet Oncology, has found that nivolumab reduced the rate of clinically meaningful deterioration compared with investigator’s choice among platinum-refractory patients being treated for recurrent or metastatic head and neck cancer.
Read More
Infusing a Sense of Urgency in Cancer Care: The Biden Cancer Initiative
June 27th 2017On Monday, June 26, 2017, the Biden Foundation announced the launch of the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care.
Read More
Understanding Stakeholder Objectives, and Aligning Them, in Cancer Care
June 26th 2017At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, the discussion included raw material short supplies, pragmatic trials, risk-sharing, and understanding these challenges to meet stakeholder goals.
Read More
Diagnostic Immunoassays Could Spare Patients High-Risk Pancreatic Resection
June 25th 2017Researchers at Indiana University have confirmed the clinical utility of 2 laboratory tests that can distinguish benign pancreatic cancer lesions that mimic early signs of cancer and spare patients of unnecessary pancreatic cancer screenings or surgeries.
Read More
Developing a Creative Strategy to Present the Value of Oncology Drugs
June 22nd 2017At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, Sriram Shankar, senior consultant, INC Strategy Consulting, shared his thoughts on the implications of value frameworks for payer strategy.
Read More
Diagnostic Test Brings a Precision Medicine Approach to Prostate Cancer Drug
June 19th 2017A collaborative study among scientists working across 3 continents has found a strong association between circulating free DNA in patients being treated with olaparib (Lynparza) for prostate cancer and disease outcome.
Read More
Instilling Value Early in Product Development: A Pharma Perspective
June 16th 2017At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, pharmaceutical developers shared strategies on how a “value” culture can be infused right from the preclinical stage of oncology product development.
Read More
Genome-Wide Association Studies Identify Novel Risk Loci for Testicular Cancer
June 14th 2017A meta-analysis spearheaded by The International Testicular Cancer Consortium has identified new susceptibility loci in the human genome that can increase a person’s risk of developing inherited testicular germ cell tumors.
Read More
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13th 2017Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.
Read More
NEJM Study Oncologists: Do Small Breast Cancers Indicate Overdiagnosis?
June 8th 2017A new study analyzing breast cancer data in the SEER database has concluded that small tumors detected following a mammography might be small because they are slow-growing, and not necessarily because they were detected early.
Read More
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 6th 2017A discussion at the 2017 American Society of Clinical Oncology Annual Meeting addressed the practical solutions to address the financial toxicity of cancer care and identified leads for future intervention studies aiming to prevent or reduce this burden.
Read More
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 5th 2017Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.
Read More